VGA039 (VEGA Program)
von Willebrand Disease (VWD)
Key Facts
About Star Therapeutics
Star Therapeutics is a private, late clinical-stage biotech founded in 2018 and headquartered in South San Francisco, California. The company is developing novel antibody therapies with an initial focus on bleeding disorders, led by its pivotal Phase 3 candidate, VGA039, which has shown promising early data. With a leadership team experienced in first-in-class antibody development and over $300 million in funding, Star is positioning itself as a potential leader in hemostatic therapeutics while exploring broader applications for its platform.
View full company profileAbout Star Therapeutics
Star Therapeutics is a private, late clinical-stage biotech founded in 2018 and headquartered in South San Francisco, California. The company is developing novel antibody therapies with an initial focus on bleeding disorders, led by its pivotal Phase 3 candidate, VGA039, which has shown promising early data. With a leadership team experienced in first-in-class antibody development and over $300 million in funding, Star is positioning itself as a potential leader in hemostatic therapeutics while exploring broader applications for its platform.
View full company profile